An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants

Parsaclisib, a selective, potent phosphatidylinositol 3‐kinase delta inhibitor being developed for the treatment of cancer and autoimmune diseases, is primarily metabolized by cytochrome P450 (CYP) 3A4. This study assessed the pharmacokinetics (PK) and safety of parsaclisib alone or combined with it...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Pharmacol
Main Authors: Li, Jia, Rockich, Kevin, Yuska, Brad, Zhou, Gongfu, Epstein, Noam, Punwani, Naresh, Chen, Xuejun, Yeleswaram, Swamy
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
NON COVID ARTICLES
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7586811/
https://ncbi.nlm.nih.gov/pubmed/32515832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1653
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items